



Checkpoint Regulator, Neihulizumab, as a Novel Therapy for Immunological Diseases



Title: Checkpoint Regulator, Neihulizumab, as a Novel Therapy for Immunological Diseases

Time: 4:30 pm

Day: October 6, 2021

Details:

- P-selectin glycoprotein ligand-1 (PSGL-1), a versatile molecule well known for its role in mediating leukocyte trafficking into inflammatory tissues, has also immune modulatory functions in various immune cells. It has been hypothesized that agents specific for PSGL-1 with agonistic function can be applied for immune modulation in autoimmune setting.
- Neihulizumab (AbGn-168H, Altrubio Inc, San Francisco, CA, USA) is a humanized IgG4 monoclonal antibody that binds to human PSGL-1 and regulates T cell functions.
- It has been tested in psoriasis, psoriatic arthritis, ulcerative colitis and graft-versus-host diseases with clear signs of efficacy and excellent safety profile.
- PSGL-1 agonism is a valid strategy for developing therapeutic modalities in treating T cell-mediated autoimmune diseases.

Speakers:



Judy Chou

Company: AltruBio

Job title: President & Chief Executive Officer